GlobeNewswire

Nasdaq and Celent Publish Global C-Suite Study on Capital Markets Infrastructure Technology

Dela

Report explores C-Suite mindset on R&D, adoption of new business models and technology spe

 

 

NEW YORK and STOCKHOLM, Sweden, June 26, 2018 (GLOBE NEWSWIRE) -- During its biennial Technology of the Future conference in Stockholm, Nasdaq Inc. (Nasdaq:NDAQ), in collaboration with Celent, today revealed the results of a new study of market infrastructure (MI) senior technology and strategy officers that uncovered three important trends: the factors that are driving changes in market infrastructure, how MIs are using technology to support business strategies and how technology spend is evolving.

The report was conducted through in-depth discussions with C-suite executives (including CEOs, COOs, CTOs, CIOs and Heads of Strategy) representing 20 different MI organizations across North America, Europe, Middle East, Asia, and Latin America.

"As market infrastructure operators, our economies are reliant on us to provide a seamless ability for buyers and sellers to come together in a fair environment, find the right price, and trade instantaneously. Technology is the lynchpin of this ecosystem," said Brad Peterson, Chief Technology & Chief Information Officer, Nasdaq. "Our study has shown that nearly all executives interviewed worldwide are looking across borders and embracing the global interconnectedness of our markets. They are tapping technologies such as cloud, APIs, and machine intelligence, while also recognizing the inflexibility and limitations of legacy systems in achieving goals around business expansion and technology scalability. We believe this is a welcomed step in the right direction for the health and longevity of our economies."

"The market infrastructure providers that will stay relevant in the digital age must be agile and flexible players that are not afraid of change," said Josephine de Chazournes, Senior Analyst at Celent and co-author of the report. "They have to be able to reinvent themselves in adjacent businesses, and grasp opportunities even if they are not in their DNA."

"The promised land of digitized capital markets infrastructure does not come without new risks - cyber risk is already a big concern, while money laundering, fraud, and market abuse risks are growing," said Arin Ray, Senior Analyst at Celent and co-author of the report. "It will take industry wide efforts to mitigate the risks."

The key takeaways from the study include:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/89d2c87d-0428-4c8a-94a9-e5d4c278069b

  • Technology is playing an increasingly important role in supporting growth plans. From 10% to 50% of MIs' technology budgets is spent to change the legacy technology and innovating vs. 90% to 50% for the maintenance of systems. The bigger the player the more already amortized are the maintenance costs and thus the split tends to be closer to 50%-50%.

  • Data and analytics are becoming major revenue drivers, and all MIs surveyed are transforming data management practices with plans to offer new data solutions and delivery options such as data-as-a-service. The next goal is to develop advanced analytical tools with AI and machine learning (ML) to create new solutions for investment decision support, risk management and compliance. 
     
  • There is tremendous interest in adopting new technology such as cloud, artificial intelligence (AI), machine learning (ML), and distributed ledger technology (DLT) because they can help develop innovative solutions, new business models, and contribute to significant operational improvements. New solutions are being developed with of one the new technologies (open architecture, cloud enabled, and/or application programming interfaces (APIs)), or at least with provisions to easily incorporate them in the future by 95%of market infrastructures surveyed.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ab9b7f2f-093c-481b-b2cb-3c87c489d597

  • Cloud adoption is becoming mainstream for all participants in our discussion except only one, with 40% already using cloud in some (non-core) functions, and an additional 45% working on pilots. Many large players are finalizing their cloud partners and strategies, and smaller players expect their vendors to deliver the promises of cloud to them. Data privacy and sovereignty issues are a challenge for some players, and clearer regulations and industry standards will be needed for expediting cloud adoption for production data.

  • Artificial intelligence is gaining prominence with leading MIs developing advanced analytical offerings with AI and ML and leveraging the cloud. It is also being used in operations, especially in risk management for surveillance, fraud, and cyber-risk monitoring. Data management and model governance issues can be challenging for some MIs in adopting AI, and many are using AI-enabled solutions from leading international vendors. In the study, 35% of all institutions mentioned they are already using AI, and an equal share working on pilots. On the other hand, robotic process automation (RPA), which is a simpler and more cost-effective technology to automate manual processes, is widely used, and its adoption is growing - 70% of discussion participants mentioned they are already using RPA. 

  • Distributed ledger technology promises to be transformative, especially in post-trade market infrastructure, and almost all players are involved in DLT development projects through partnerships, joint ventures, and industry consortia. Numerous use cases of DLT are emerging in peripheral functions. Because it is still a new and complex technology, not every MI is able to experiment with it individually, but 70% of MIs in the study sample are involved in accelerators, pilots, or industry consortia. 
     
  • Market infrastructure players are increasingly looking for third party solutions because they are cost effective, and compliant with the latest standards and regulations. In core MI functions, there is growing preference to buy and customize third party solutions instead of reinventing the wheel.

  • Cyber-risk is the biggest concern for market infrastructure providers. Indeed all the respondents cited it as such. As MIs engage more with third party providers and fintech startups, everyone in the ecosystem must improve their cyber-security measures, because the system is only as strong as its weakest link. Despite growing recognition of the risks, few are taking concrete steps to address them. It will take industry-wide efforts to overcome these challenges because the new risks will be hard to mitigate by acting in isolation.

To download a copy of the study, please visit here.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $13 trillion.

About Celent

Celent is a research, advisory, and consulting firm focused on financial services technology. We help our Clients make better decisions about technology. Celent publishes research identifying trends and best practices in financial services technology and conducts consulting engagements for financial institutions looking to use technology to enhance existing business processes or launch new business strategies. With a team of internationally-based analysts, Celent is uniquely positioned to offer strategic advice and market insights on a global basis. Celent is a division of the Oliver Wyman Group, which is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC). 

For Media Inquiries:

Nasdaq
Ryan Wells
ryan.wells@nasdaq.com
Direct: +44 (0) 20 3753 2231
Mobile: +44 (0) 7809 596 390

NDAQG




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nasdaq via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum